Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease
NCT: NCT07843004 · RECRUITING
Brief Summary
Doctors are testing a new tool called EchoNext to see if it can help find heart problems earlier. EchoNext looks at the heart's electrical test, called an ECG, and uses artificial intelligence (AI) to check for signs of structural heart disease (SHD). SHD includes conditions like weak heart pumping, heart valve problems, or extra thickening of the heart muscle. These problems are common but often go undiagnosed until they cause serious issues like heart failure or stroke. The main questions this study will answer are: Can EchoNext alerts help emergency doctors find hidden heart problems sooner? Does this lead to more follow-up heart tests, like an echocardiogram (heart ultrasound)? What this means for patients: If a person has an ECG in the Emergency Department, the EchoNext tool may be used to check their heart. If the tool finds something unusual, their doctor may receive an alert and may then recommend further heart tests or follow-up care. This study will help researchers learn if using EchoNext improves early diagnosis and treatment of heart disease.
Frequently Asked Questions
What is Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease?
Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease is a clinical trial registered under NCT07843004. Current status: RECRUITING.
What is the status of NCT07843004?
The current status of NCT07843004 (Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease) is: RECRUITING.
When did Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease start?
Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease started on 2026-09-16.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.